Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoledronic acid + calcium + vitamin d
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous (zoledronic Acid), Oral (calcium, Vitamin D)
01
Overview
A combination therapy consisting of **zoledronic acid** (a third-generation bisphosphonate), **calcium**, and **vitamin D** is used to prevent or treat osteoporosis and other conditions involving bone loss, such as those associated with cancer or Paget's disease. Zoledronic acid inhibits osteoclast-mediated bone resorption, thereby increasing bone mineral density and decreasing fracture risk. Calcium and vitamin D are essential for bone formation and maintenance; their supplementation reduces the risk of hypocalcemia, which may be induced by bisphosphonates. This combination is especially used in patients receiving zoledronic acid, as adequate levels of calcium and vitamin D are crucial for safety and efficacy[1][4][7].
- Brand names
- ReclastZometa
- Other names
- zoledronatecalcium supplementvitamin d supplement
02
Targets
FDPS (Farnesyl pyrophosphate synthase)CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on zoledronic acid + calcium + vitamin d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoledronic acid + calcium + vitamin d.